Glyconanoparticle Absorption Study Service
Overview of Glyconanoparticle Absorption Study
Relying on the high-quality GlycoNano™ Platform, CD BioGlyco provides satisfactory Glyconanoparticle Preclinical Study programs. As a novel drug delivery system, glyconanoparticles have unique physicochemical properties and biocompatibility, which improve the solubility, permeability, and stability of drugs, thus enhancing their efficacy and reducing side effects. However, their pharmacokinetic properties in organisms, especially the absorption process, have an important impact on the effectiveness and safety of drugs. Therefore, it is important to carry out absorption study services on the pharmacokinetics of glyconanoparticles to guide drug design, optimize dosing regimens, and improve therapeutic efficacy. With advanced technology and a professional team, CD BioGlyco provides professional glyconanoparticle absorption study services.
In-depth Insight: Pharmacokinetic Absorption Study of Glyconanoparticles
In Vitro Simulation Studies
Our company provides services for water solubility assessment, permeability studies, and transporter studies.
- Permeability studies
- Our company offers non-cellular models (PAMPA) and a variety of cellular models for permeability studies. The cell types we commonly use include but are not limited to, wild-type Madin-Darby canine kidney type II (MDCK-II) cells, multidrug resistance 1 (MDR1)-MDCK II cells, melanoma cells, opossum kidney (OK) cells, human bronchial epithelial (HBE) cells, and Caco-2 cells.
- In vitro permeability assays provide permeability data including compound solubility, cellular accumulation, efflux transport, and the ability to regulate intercellular tight junctions. We offer specialized uni- and bi-directional and concentration-dependent permeability analysis services.
- Transporter studies
- Transporters influence in vivo processes such as drug absorption, distribution, and elimination, which in turn affects drug efficacy and safety. We offer a variety of in vitro models for the evaluation of transporter-mediated drug-drug interactions. We focus on the evaluation of substrates or inhibitors for specific transporters. Cell types commonly used in our company include human embryonic kidney cells (HEK 293 cells), MDR1-MDCK I and MDR1-MDCK II cells, and Caco-2 cells.
In Vivo Metabolic Studies
- Bioavailability assessment
- Carrier-based nanomedicines enter the body through various routes of administration such as intravenous, subcutaneous, or intramuscular, and the route of administration is an important factor in determining the absorption of nanomedicines.
- Our researchers provide an analysis of the effect of different routes of administration such as intravenous, intraperitoneal, subcutaneous, intradermal, intrathecal, etc. on absorption.
- Blood and tissue testing
- The difference between carrier-based nanomedicine and ordinary drugs is the existence of its functional unit drug-carrying particles. Our company offers services for the determination of the concentration of free and loaded drugs in the blood.
- We provide the service of measuring the concentration of carrier materials and drug-carrying particles in the blood, which helps clients analyze in-depth information about the release kinetics of drugs and the depolymerization/degradation kinetics of carriers in vivo.
- Specifically, for some nanocarrier drugs (e.g., polyethylene glycolized drug-carrying particles), the phenomenon of accelerated blood clearance (ABC) occurs in vivo after multiple injections. We offer specialized ABC monitoring services.
- Our researchers offer somatic small bowel perfusion studies and gastrointestinal stability (chemical, microbiological, enzymatic) studies.
Workflow

Applications
- Our absorption study can be used to investigate the cellular pharmacokinetic-pharmacodynamic correlation of glyconanoparticles.
- Our absorption study can be used to analyze drug permeation and transport pathways to interpret drug absorption and distribution in the body.
- Our absorption study can be used to evaluate and predict the efficacy of drugs and the toxic side effects they may cause.
Advantages of Us
- Our absorption study provides not only bioavailability prediction but also distribution prediction of the compound in the organism, e.g., prediction of the permeability of the compound in the central system or blood-brain barrier.
- Our company offers a wide range of animal models, cellular models, and in-cohort injections to meet the needs of our clients in different studies.
- Our company has a professional data analysis team to help clients organize and analyze all experimental data.
Publication Data
Technology: Ionic gelation method, Nano-zeta sizer, Scanning electron microscopy (SEM), High-pressure liquid chromatography (HPLC)
Journal: Arabian Journal of Chemistry
Published: 2021
IF: 5.3
Results: In this study, researchers prepared mannose-anchored preactivated thiolated chitosan nanoparticles (MPTCht-NPs). The researchers tested the nanoparticles for in vitro encapsulation (EE%), zeta potential (mV), permeability, in vivo pharmacokinetics, toxicity, and immunomodulation. The results showed that MPTCht-NPs showed a 19-fold increase in permeability and a 16-fold increase in oral bioavailability compared to conventional Rifampicin.
Fig.1 Microscopic examination of tissue histology slides. (Rauf, et al., 2021)
Frequently Asked Questions
- What are the applications of glyconanoparticles in medicine and health?
The research of glyconanoparticles in the field of medicine and health mainly focuses on cell separation and immunoassay, DNA isolation, nucleic acid hybridization, guided drug carriers, targeted drugs, immobilized enzymes, nuclear magnetic resonance (NMR) contrast agents, drug-carrying systems, and tumor-targeted therapies. - How do glyconanoparticles enter cells?
Glyconanoparticles enter the cell mainly through endocytosis, and their endocytosis pathways include giant cytosol, lattice protein-mediated endocytosis, folliculin-mediated endocytosis, and lattice protein/folliculin-independent endocytosis. The endocytosis process is closely related to both the nature of the nanoparticle itself and the nature of the cell. Our company provides services to analyze the effect of surface charge, particle size, shape, and nature of the carrier on endocytosis.
CD BioGlyco provides professional glyconanoparticle absorption study services and helps clients solve problems encountered in Pharmacokinetic Studies. Our high-quality research platforms and careful, patient service have been praised by clients all over the world. Feel free to contact us to customize your research program!
Reference
- Rauf, A.; et al. Design of mannose-coated Rifampicin nanoparticles modulating the immune response and Rifampicin induced hepatotoxicity with improved oral drug delivery. Arabian Journal of Chemistry. 2021, 14(9): 103321.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




